- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00986180
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
December 17, 2012 updated by: Ortho-McNeil Janssen Scientific Affairs, LLC
A Randomized, Double-Blind, Parallel-Group Study of NUCYNTA (Tapentadol) Immediate Release vs. Oxycodone Immediate Release for the Treatment of Acute Low Back Pain
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the treatment of acute low back pain.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, outpatient, multicenter, double-blind study (blinded to patient and to study doctor) comparing NUCYNTA to oxycodone IR in the treatment of patients with acute (new onset) low back pain who also have associated leg pain that radiates (travels down) below the knee.
Patients will be screened for study eligibility at Visit 1.
The study will be explained and informed consent will be obtained.
Potential patients must satisfy all eligibility criteria to be enrolled in the study.
Eligible candidates will proceed to the Double-Blind Treatment Phase.
At the time of study entry, all prohibited medications will be discontinued and will be disallowed throughout the study.
All patients will call into an interactive voice response system (IVRS) to complete a pain assessments twice daily throughout the study.
Patients who discontinue early for any reason will be instructed to contact the study site to complete final assessments, prior to taking supplemental pain medication if applicable, and to schedule a final study visit.
All patients will return to the study site on Day 5 (Visit 2) where they will be evaluated by study personnel and, as appropriate, continue with study treatment for an additional 5 days.
Patients will return to the study site for the final visit on Day 10/End of Study (Visit 3) when they will have all final study assessments.
The treatment duration will be up to 10 days.
The sponsor will collect adverse events starting with the signing of the informed consent form.
Adverse events will be reported by the subject for the duration of the study.
Any clinically significant abnormalities persisting at the end of the study will be followed by the investigator until resolution or until a clinically stable endpoint is reached.
Blood samples for serum chemistry and hematology and a urine sample for urinalysis will be collected.
The investigator will review the laboratory report, document this review, and record any clinically relevant changes occurring during the study.
The following tests will be performed by the central laboratory: Urine Pregnancy Testing for women of childbearing potential only, Urine Drug Screen, Vital Signs (pulse rate and blood pressure), Physical Examination, Neurological Examination, and Vomiting Assessment.
The study will be conducted at approximately 80 sites in the United States (US).
Patients will be randomized to one of the two following treatment groups: NUCYNTA 50, 75 or 100 mg every 4 to 6 hours up to 10 days as needed for pain.
Oxycodone IR 5, 10 or 15 mg every 4 to 6 hours as needed for pain.
Patients will begin treatment on Day 1 with one "lower dose" capsule of study drug (NUCYNTA 50 mg or oxycodone IR 5 mg).
Subsequent dose adjustments will be made by study patients, as needed, to achieve a dose that provides a meaningful improvement in their pain intensity
Study Type
Interventional
Enrollment (Actual)
667
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
Arkansas
-
Jonesboro, Arkansas, United States
-
-
California
-
Fresno, California, United States
-
Garden Grove, California, United States
-
Glendale, California, United States
-
Laguna Hills, California, United States
-
Palm Springs, California, United States
-
Pismo Beach, California, United States
-
Wildomar, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Fairfield, Connecticut, United States
-
-
Florida
-
Boynton Beach, Florida, United States
-
Clearwater, Florida, United States
-
Edgewater, Florida, United States
-
Jacksonville, Florida, United States
-
Lake Worth, Florida, United States
-
Miami, Florida, United States
-
Newport Richey, Florida, United States
-
Oldsmar, Florida, United States
-
Pembroke Pines, Florida, United States
-
Saint Cloud, Florida, United States
-
Tampa, Florida, United States
-
West Palm Beach, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Savannah, Georgia, United States
-
-
Indiana
-
Avon, Indiana, United States
-
Evansville, Indiana, United States
-
-
Kansas
-
Overland Park, Kansas, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Louisiana
-
Covington, Louisiana, United States
-
Mandeville, Louisiana, United States
-
Metairie, Louisiana, United States
-
New Orleans, Louisiana, United States
-
Sunset, Louisiana, United States
-
-
Massachusetts
-
Fall River, Massachusetts, United States
-
N Dartmouth, Massachusetts, United States
-
-
Michigan
-
Kalamazoo, Michigan, United States
-
-
Missouri
-
Florissant, Missouri, United States
-
Springfield, Missouri, United States
-
Washington, Missouri, United States
-
-
Nevada
-
Henderson, Nevada, United States
-
Pahrump, Nevada, United States
-
-
New Jersey
-
Atco, New Jersey, United States
-
Blackwood, New Jersey, United States
-
Cherry Hill, New Jersey, United States
-
-
New York
-
North Massapequa, New York, United States
-
Williamsville, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Hickory, North Carolina, United States
-
Mooresville, North Carolina, United States
-
Winston Salem, North Carolina, United States
-
-
Ohio
-
Akron, Ohio, United States
-
Andover, Ohio, United States
-
Beavercreek, Ohio, United States
-
Centerville, Ohio, United States
-
Cincinnati, Ohio, United States
-
Marion, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States
-
Tyrone, Pennsylvania, United States
-
-
South Carolina
-
Murrells Inlet, South Carolina, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Bryan, Texas, United States
-
Bulverde, Texas, United States
-
Houston, Texas, United States
-
Lake Jackson, Texas, United States
-
Plano, Texas, United States
-
San Antonio, Texas, United States
-
Sugar Land, Texas, United States
-
-
Utah
-
Clinton, Utah, United States
-
Orem, Utah, United States
-
-
Virginia
-
Danville, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At Visit 1 (study entry) patients must have a medical history and physical and neurological examinations that support a clinical diagnosis of acute low back pain that is felt down to the lower leg below the knee with the onset no longer than 30 days before Visit 1
- At Visit 1 patients must report qualifying pain intensity scores
- Patients must be appropriate candidates for treatment with oral opioid pain medication in the investigator's clinical judgment
- Patients must be able to appropriately verbalize pain characteristics and to complete all protocol required measurements/assessments without assistance
- Patients must be medically stable on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening
Exclusion Criteria:
- History of back (cervical, thoracic or lumbosacral) pain =50% of the time in the 1 year prior to the first visit
- History of any low back pain episode, with the exception of the current acute low back pain episode, within 3 months prior to the first visit that was greater than mild in pain intensity, or was associated with disability (e.g., loss of time from work, family, or activities of daily living), or necessitated the use of an opioid (narcotic) analgesic including tramadol
- Medical history or physical examination results that suggest the acute low back pain or any of the neurological symptoms or signs are caused by a serious medical condition (e.g., fever, chills, unexplained weight loss, bowel or urinary bladder dysfunction or incontinence, bilateral leg weakness, progressive weakness, paralysis)
- There is a high probability for surgical intervention for the back pain during the projected time on the study or that there will be an increase in the severity of the leg pain or deficits
- Had either a surgical procedure involving the spine or intervertebral discs in the lower back region within 1 year prior to Visit 1 or had >1 surgical procedure(s) involving the spine or intervertebral discs in the lower back region
- has any painful condition that could interfere with the study assessments or with the patient's ability to differentiate the pain associated with the acute low back pain episode from pain associated with another condition
- History of severe lumbar spinal stenosis, fibromyalgia, or ankylosing spondylitis
- history of epilepsy or recurrent seizures
- Unable or unwilling to discontinue all prohibited medications at the time of randomization and during the time of their participation in the study
- Known or suspected history of alcohol or drug abuse based on medical history, physical examination, urine drug screening, or the investigator's clinical judgment
- History of cancer malignancy within 2 years prior to the first visit, with the exception of basal cell skin carcinoma
- Have filed or plan to file a worker's compensation claim for any issue related to the current acute low back pain episode
- Currently involved in litigation or plan to seek legal recourse for any issue related to their acute low back pain
- Known allergies, hypersensitivity, or intolerance to tapentadol or the comparator (oxycodone) or any excipients used in their manufacture
- Had previously been enrolled in a tapentadol clinical study
- is pregnant or are breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
|
50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
|
Active Comparator: 002
Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
|
5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 120 Hours (With Imputation)
Time Frame: 0 hour (prior to first dose) and 120 hours
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 120 hours.
|
0 hour (prior to first dose) and 120 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 2 Days (With Imputation)
Time Frame: Day 0 and Day 2
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 2 days.
|
Day 0 and Day 2
|
SPID for Low Back Pain - Summary Statistics at 3 Days (With Imputation)
Time Frame: Day 0 and Day 3
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 3 days.
|
Day 0 and Day 3
|
SPID for Low Back Pain - Summary Statistics at 10 Days (With Imputation)
Time Frame: Day 0 and Day 10
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 10 days.
|
Day 0 and Day 10
|
SPID for Index Leg Pain - Summary Statistics at 2 Days (With Imputation)
Time Frame: Day 0 and Day 2
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 2 days.
|
Day 0 and Day 2
|
SPID for Index Leg Pain - Summary Statistics at 3 Days (With Imputation)
Time Frame: Day 0 and Day 3
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 3 days.
|
Day 0 and Day 3
|
SPID for Index Leg Pain - Summary Statistics at 5 Days (With Imputation)
Time Frame: Day 0 and Day 5
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 5 days.
|
Day 0 and Day 5
|
SPID for Index Leg Pain - Summary Statistics at 10 Days (With Imputation)
Time Frame: Day 0 and Day 10
|
Pain intensity is an 11-point numerical rating scale (NRS).
0=no pain, 10=Pain as bad as you can imagine.
The pain intensity difference (PID) was to be calculated as baseline pain minus current pain at each assessment time point.
SPID is a weighted sum of PID over a specified time period, say 10 days.
|
Day 0 and Day 10
|
Total Pain Relief (TOTPAR) for Low Back Pain - Summary Statistics at 5 Days
Time Frame: Day 0 and Day 5
|
Pain Relief - 5-Point Numerical Rating Scale, 0=None, 4=Complete.
Total Pain Relief (TOTPAR) is a weighted sum of pain relieve over a specified time period, say 5 days.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Continuous Pain Day 5
Time Frame: Day 0 and Day 5
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Continuous pain subscale descriptors include: throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Continuous Pain Day 10/Last Visit
Time Frame: Day 0 and Day 10
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Continuous pain subscale descriptors include: throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, and tender.
|
Day 0 and Day 10
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Intermittent Pain Day 5
Time Frame: Day 0 and Day 5
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Intermittent pain subscale descriptors include: shooting pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, and piercing.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Intermittent Pain Day 10/Last Visit
Time Frame: Day 0 and Day 10
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Intermittent pain subscale descriptors include: shooting pain, stabbing pain, sharp pain, splitting pain, electric-shock pain, and piercing.
|
Day 0 and Day 10
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Neuropathic Pain Day 5
Time Frame: Day 0 and Day 5
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Predominantly neuropathic pain subscale descriptors include: hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or "pins and needles" and numbness.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Neuropathic Pain Day 10/Last Visit
Time Frame: Day 0 and Day 10
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Predominantly neuropathic pain subscale descriptors include: hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or "pins and needles" and numbness.
|
Day 0 and Day 10
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Affective Descriptors Day 5
Time Frame: Day 0 and Day 5
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Affective subscale descriptors include: tiring-exhausting, sickening, fearful, and punishing-cruel.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Affective Descriptors Day 10/Last Visit
Time Frame: Day 0 and Day 10
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
Subscale scores are calculated as the mean of the items in that subscale ranged from 0 to 10. Affective subscale descriptors include: tiring-exhausting, sickening, fearful, and punishing-cruel.
|
Day 0 and Day 10
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Total Score Day 5
Time Frame: Day 0 and Day 5
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
The total SF-MPQ-2 scale score is calculated as the mean of all 22 items.
The range of the total score is 0 to 10.
|
Day 0 and Day 5
|
SF-MPQ-2 - Change From Baseline Values: Subscale and Total Scores - Total Score Day 10/Last Visit
Time Frame: Day 0 and Day 10
|
Short-Form McGill Pain Questionnaire - 2 (SF-MPQ-2) is a 22-question instrument.
Each item lists different qualities of pain or related symptoms and is scored using an 11-point NRS ranging from (pain or symptom is not present) to 10 (worst possible pain).
The total SF-MPQ-2 scale score is calculated as the mean of all 22 items.
The range of the total score is 0 to 10.
|
Day 0 and Day 10
|
Patient Global Impression of Change at End of Study
Time Frame: Day 0 and Day 10/last visit
|
Patient Global Impression of Change (PGIC) assesses the subject's global improvement since starting study treatment using a 7-point NRS (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse).
|
Day 0 and Day 10/last visit
|
Patient Global Impression of Change at End of Study
Time Frame: Day 0 and Day 10/lst visit
|
Patient Global Impression of Change (PGIC) assesses the subject's global improvement since starting study treatment using a 7-point NRS (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse).
|
Day 0 and Day 10/lst visit
|
Clinician Global Impression of Change at End of Study
Time Frame: Day 0 and Day 10/last visit
|
Clinician Global Impression of Change (CGIC) assesses the subject's global improvement since starting study treatment using a 7-point NRS (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse).
|
Day 0 and Day 10/last visit
|
Satisfaction With Treatment at Day 5
Time Frame: Day 0 and Day 5
|
The subject's satisfaction with treatment was assessed using a 7-point scale (1=Very satisfied, 2=Somewhat satisfied, 3=Slightly satisfied, 4=Neither satisfied nor dissatisfied, 5=Slightly dissatisfied, 6=Somewhat dissatisfied, 7=Very dissatisfied).
|
Day 0 and Day 5
|
Satisfaction With Treatment at End of Study
Time Frame: Day 0 and Day 10/last visit
|
The subject's satisfaction with treatment was assessed using a 7-point scale (1=Very satisfied, 2=Somewhat satisfied, 3=Slightly satisfied, 4=Neither satisfied nor dissatisfied, 5=Slightly dissatisfied, 6=Somewhat dissatisfied, 7=Very dissatisfied).
|
Day 0 and Day 10/last visit
|
Incidence of 30% Responders Without Nausea or Vomiting at Day 5
Time Frame: Day 0 and Day 5
|
Number of subjects had ≥ 30% reduction from baseline in low back pain intensity without nausea or vomiting reported.
|
Day 0 and Day 5
|
Incidence of 50% Responders Without Nausea or Vomiting at Day 5
Time Frame: Day 0 and Day 5
|
Number of subjects had ≥ 50% reduction from baseline in low back pain intensity without nausea or vomiting reported.
|
Day 0 and Day 5
|
Summary of Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation
Time Frame: Day 0 and Day 10/last visit
|
Day 0 and Day 10/last visit
|
|
Summary of Subjects Having Nausea as a Treatment-Emergent Adverse Event
Time Frame: Day 0 and Day 10/last visit
|
Number of subjects that reported nausea as a treatment-emergent adverse event during the study.
|
Day 0 and Day 10/last visit
|
Summary of Subjects Having Vomiting as a Treatment-Emergent Adverse Event
Time Frame: Day 0 and Day 10/last visit
|
Number of subjects that reported vomiting as a treatment emergent adverse event during the study.
|
Day 0 and Day 10/last visit
|
Summary of Subjects Having Constipation as a Treatment-Emergent Adverse Event
Time Frame: Day 0 and Day 10/last visit
|
Number of subjects that reported constipation as a treatment emergent adverse event during the study.
|
Day 0 and Day 10/last visit
|
Summary of Subjects Having Pruritus as a Treatment-Emergent Adverse Event
Time Frame: Day 0 and Day 10/last visit
|
Number of subjects that reported pruritus as a treatment emergent adverse event during the study.
|
Day 0 and Day 10/last visit
|
Kaplan-Meier First Time to 30% Response From Baseline for Low Back Pain
Time Frame: Day 0 and Day 10/last visit
|
30% response means >= 30% reduction from baseline in low back pain intensity score.
|
Day 0 and Day 10/last visit
|
Kaplan-Meier First Time to 50% Response From Baseline for Low Back Pain
Time Frame: Day 0 and Day 10/last visit
|
50% response means >= 50% reduction from baseline in low back pain intensity score.
|
Day 0 and Day 10/last visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
September 25, 2009
First Submitted That Met QC Criteria
September 25, 2009
First Posted (Estimate)
September 29, 2009
Study Record Updates
Last Update Posted (Estimate)
December 19, 2012
Last Update Submitted That Met QC Criteria
December 17, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR015643
- R331333PAI3025 (Other Identifier: Ortho-McNeil Janssen Scientific Affairs, LLC)
- KF5503/51 (Other Identifier: Grünenthal)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on NUCYNTA
-
Janssen Scientific Affairs, LLCWithdrawnPain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or KneeUnited States
-
Grünenthal GmbHCompletedOsteoarthritis | Chronic PainGermany, United Kingdom, France, Poland, Spain
-
Grünenthal GmbHTerminatedOsteoarthritis | Chronic PainGermany, United Kingdom, Spain, Australia, Denmark, Poland
-
Grünenthal GmbHTerminatedPain | Cancer | Chronic PainBulgaria, Hungary, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia
-
Janssen PharmaceuticaWithdrawnModerate to Severe Chronic Non-cancer Pain
-
Grünenthal GmbHTerminatedPain | Low Back Pain | Chronic Pain | Neuropathic Pain | Nociceptive PainBelgium, Czechia, France, Germany, Netherlands, Poland, Spain, Switzerland
-
Grünenthal GmbHCompletedLow Back Pain | Chronic PainAustria, Germany, United Kingdom, Croatia, France, Italy, Poland, Spain, Switzerland
-
Janssen PharmaceuticaWithdrawnModerate to Severe Acute Non-Cancer Pain
-
Grünenthal GmbHCompleted
-
Grünenthal GmbHDepomedTerminatedModerate to Severe Acute Postoperative PainUnited States, United Kingdom, Poland